



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁷ : A61K 51/04, C07D 243/24</p>	<p>A1</p>	<p>(11) International Publication Number: WO 00/61195</p> <p>(43) International Publication Date: 19 October 2000 (19.10.00)</p>
<p>(21) International Application Number: PCT/US00/10093</p> <p>(22) International Filing Date: 14 April 2000 (14.04.00)</p> <p>(30) Priority Data: 09/292,067 14 April 1999 (14.04.99) US</p> <p>(71) Applicants: DIATIDE, INC. [US/US]; 9 Delta Drive, Londonderry, NH 03053 (US). GENENTECH, INC. [US/US]; One DNA Way, South San Francisco, CA 94080 (US).</p> <p>(72) Inventors: DEAN, Richard, T.; 43 Kind Road, Bedford, NH 03110 (US). LISTER-JAMES, John; 25 Old Stone Way, Bedford, NH 03110 (US). VENUTI, Michael, C.; 207 Montcalm Street, San Francisco, CA 94110 (US). SOMERS, Todd, C.; 1011 Buckland Avenue, San Carlos, CA 94070 (US).</p> <p>(74) Agent: McDANIELS, Patricia, A.; Diatide, Inc., 9 Delta Drive, Londonderry, NH 03053 (US).</p>	<p>(81) Designated States: AE, AL, AU, BA, BB, BG, BR, CA, CN, CR, CU, CZ, DM, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, UZ, VN, YU, ZA, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>	
<p>(54) Title: BENZODIAZEPINE DERIVATIVES FOR IMAGING THROMBI</p> <p>(57) Abstract</p> <p>The invention provides compounds comprising glycoprotein IIb/IIIa receptor-binding benzodiazepine derivatives covalently linked to metal ion chelators. The compounds of the invention may be labeled with a radionuclide such as ^{99m}Tc and used to image thrombi.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

BENZODIAZEPINE DERIVATIVES FOR IMAGING THROMBI

5 The present invention relates to the field of diagnostic imaging of thrombosis. More particularly, the invention relates to pharmaceutical compositions for imaging thrombi.

BACKGROUND OF THE INVENTION

10 Thrombi are blood clots which form within the cardiovascular system. Formation of thrombi, *i.e.*, thrombosis, may cause local obstruction of blood vessels, for example in veins, arteries, or capillaries. Venous thrombi usually form in lower limbs and may produce acute symptoms by causing inflammation of the vessel wall or obstruction of the vein. Pieces of venous thrombi may also circulate through the
15 cardiovascular system to form a plug, or embolus, at a distant site such as the lung. Arterial thrombi are commonly associated with vascular disease such as atherosclerosis and may produce tissue ischemia (local anemia) by obstructing blood flow or by embolizing into capillaries. Thrombi may also form in the heart, for example, on inflamed or damaged valves, on tissue adjacent to myocardial infarcts, within injured
20 chambers, or on prosthetic valves.

 While all thrombi contain the protein fibrin and blood cells, the proportions of particular blood cells present and of fibrin/blood cell may differ, for example, because of the blood flow at the site of thrombus formation and thrombus age. Arterial thrombi which form at sites of high blood flow contain platelet aggregates bound together by thin
25 fibrin strands. Venous thrombi form in areas of stagnant blood flow and contain red blood cells with interspersed fibrin and fewer platelets. Thrombi which form under conditions of slow to moderate flow contain a mixture of red cells, platelets, and fibrin. Leukocytes, the white blood cells, migrate to and become incorporated into thrombi as they age. In addition, aggregated platelets in aging thrombi lyse and are replaced by
30 fibrin.


 Accurate detection of the various kinds of thrombi is necessary to choose, to optimize and to monitor treatment, which may differ by virtue of the location and nature

of the thrombus. Recently, ACUTECT™, a kit for making the ^{99m}Tc-radiolabeled peptide, apcptide, was approved for sale in the US as a radiopharmaceutical product for imaging acute deep vein thrombosis (DVT). The commercial availability of ACUTECT™ will significantly improve the accuracy of detection of acute DVT, and consequently, treatment of such thrombi. However, no radiopharmaceutical has thus far been approved for detection of other kinds of thrombi, and the most accurate methods available for detection of other venous thrombi such as pulmonary emboli and of arterial thrombi are invasive. Additional non-invasive agents capable of detecting the various kinds of thrombi are needed.

^{99m}Tc-radiolabeled apcptide binds to the GPIIb/IIIa receptor, the most abundant glycoprotein on the surface of platelets. The GPIIb/IIIa receptor is required for platelet aggregation and is a critical component of thrombus formation, functioning as the receptor for the adhesive proteins fibrinogen (the precursor of fibrin), fibronectin, von Willebrand factor, and vitronectin. The interaction between GPIIb/IIIa and its natural ligands is mediated by the tripeptide sequence arginine-glycine-aspartic acid (RGD). Apcptide contains the tripeptide —L-[S-(3-aminopropyl)cysteine]-glycine-aspartic acid—, which is believed to interact with GPIIb/IIIa.

U.S.Pat.No. 5,645,815 discloses that high quality thrombus imaging agents comprise GPIIb/IIIa receptor binding compounds which are capable of inhibiting platelet aggregation with an IC₅₀ less than about 0.3 μM. U.S.Pat.No. 5,830,856 discloses that such imaging agents may comprise GPIIb/IIIa receptor binding compounds which are capable of inhibiting platelet aggregation with an IC₅₀ less than about 1.0 μM.

One class of GPIIb/IIIa binding platelet aggregation inhibitors, disclosed in U.S.Pat.Nos. 5,403,836; 5,493,020; 5,565,449; 5,663,166; 5,674,863; 5,674,865; 5,705,890; and 5,716,951, are substituted benzodiazepinediones. The benzodiazepinedione scaffold approximates the “cupped” configuration of the RGD tripeptide, which correlates with platelet aggregation inhibitory activity. U.S.Pat.Nos. 5,403,836; 5,493,020; 5,565,449; 5,663,166; 5,674,863; 5,674,865; 5,705,890; and 5,716,951 describe several large classes of benzodiazepinedione derivatives, including derivatives of the general formula:



where R^1 , R^2 , and R^4 are each independently H or a reactive group; R^3 and R^5 are each independently H, alkyl, substituted alkyl, aryl, substituted aryl, or a combination thereof; D is hydrogen, phenyl, or lower alkyl; L^1 is a linking moiety; and Q^1 is a positively charged nitrogen-containing moiety. The substituted benzodiazepinediones of U.S.Pat.Nos. 5,403,836; 5,493,020; 5,565,449; 5,663,166; 5,674,863; 5,674,865; 5,705,890; and 5,716,951 are exclusively described as therapeutic agents.

Ku, *et al.* (1993) *J. Am. Chem. Soc.* **115**, 8861-8862 describes design and synthesis of benzodiazepine derivatives useful as inhibitors of glycoprotein IIb/IIIa receptor mediated platelet aggregation. The 1,4-benzodiazepine derivatives of Ku, *et al.* are exclusively described as potential antithrombotic agents.


U.S.Pat.No. 4,656,026 describes spin-labeled benzodiazepines for magnetic resonance imaging of brain tissue. U.S.Pat.No. 4,777,169 discloses radioiodinated benzodiazepines used in radioimmunoassays to determine benzodiazepine levels in body fluids. U.S.Pat.No. 4,885,152 describes radioiodinated and radiobrominated benzodiazepine derivatives for detection of benzodiazepine receptors in cerebral diseases. U.S.Pat.No. 4,997,771 discloses ^3H -benzodiazepines used to assay benzodiazepine receptor binding activity. U.S.Pat.No. 5,096,695 discloses radioiodinated benzodiazepine derivatives for use as brain imaging agents. WO 95/12610 discloses N-alkyl peptide chelators which may be covalently linked to a variety of ligands, including benzodiazepines, for use in complexing rhenium or technetium ions. JP 5-310711 discloses N-substituted benzodiazepin-2-one derivatives for electron spin resonance imaging of benzodiazepine receptors in brain nerves to diagnose epilepsy, parkinsonism, cerebral ischemia and cerebral edema.

SUMMARY OF THE INVENTION

The present inventors have found that benzodiazepine derivatives may be employed as effective thrombus imaging agents.

In one embodiment, the invention provides a compound comprising a
5 glycoprotein IIb/IIIa receptor binding benzodiazepine derivative covalently linked to a metal ion chelator, wherein the compound retains substantial potency, as measured in a standard assay for inhibition of platelet aggregation.

In another embodiment, the invention provides a compound having a formula:



10

wherein M is a metal ion chelator.

In another embodiment, the invention provides a scintigraphic imaging agent comprising a γ -emitting radionuclide and a compound of the invention.

In another embodiment, the invention provides a complex of a γ -emitting
15 radionuclide and a compound of the invention.

In yet another embodiment, the invention provides a ^{99m}Tc chelate of a compound comprising a glycoprotein IIb/IIIa receptor binding benzodiazepine covalently linked to a metal ion chelating moiety, wherein the compound retains substantial potency for inhibition of human platelet aggregation, as measured in a
20 standard inhibition of platelet aggregation assay, when chelated to ^{99m}Tc , and wherein the chelate contains at least one sulfur ligand bound to ^{99m}Tc .

In another embodiment, the invention provides a method of detecting a thrombus in a mammalian body, comprising the steps of administering an effective diagnostic amount of the scintigraphic imaging agent or complex of the invention to
25 the body and detecting radiation localized at the thrombus.

DETAILED DESCRIPTION OF THE INVENTION


The patent and scientific literature referenced herein establish the knowledge
5 available to those with skill in the art. The issued U.S. patents and allowed
applications are hereby incorporated by reference.

The compounds of the invention comprise a glycoprotein IIb/IIIa receptor-
binding benzodiazepine moiety and a metal ion chelating moiety. In accordance with
the invention, the terms "benzodiazepine derivative" or "benzodiazepine moiety" are
10 interchangeable and are defined as including any molecule comprising the
benzodiazepine nucleus, *i.e.*, a seven-membered ring fused to an aromatic six-
membered ring. The compounds of the invention may comprise any benzodiazepine
moiety, so long as the compound retains substantial potency, as measured by the
inhibitory concentration at 50% (IC₅₀) of the compound for human platelet
15 aggregation in a standardized assay of inhibition of platelet aggregation, such as the
assay set forth in Zucker, *Methods in Enzymology* (1989) **169**, 117-133. As defined
herein, "substantial potency" is defined as: preferably, an IC₅₀ for inhibition of human
platelet aggregation of less than about 1 μM; more preferably, an IC₅₀ for inhibition
of human platelet aggregation of less than about 0.3 μM; and most preferably, an IC₅₀
20 for inhibition of human platelet aggregation of less than about 0.1 μM.

Preferably, the substituted 1,4-benzodiazepine derivatives disclosed in Ku *et*
al., *supra*, are used as the benzodiazepine moiety of the compounds of the invention,
so long as the substituted benzodiazepine can be further derivatized for covalent
attachment of a metal ion chelator without substantially affecting the platelet
25 aggregation inhibitory activity of the benzodiazepine. Similarly, any of the substituted
benzodiazepinediones disclosed in U.S.Pat.Nos. 5,403,836; 5,493,020; 5,565,449;
5,663,166; 5,674,863; 5,674,865; 5,705,890; and 5,716,951 is employed as the
benzodiazepine moiety of the compounds of the present invention, so long as the
substituted benzodiazepinedione can be further derivatized for covalent attachment of
30 a metal ion chelator without substantially affecting the platelet aggregation inhibitory
activity of the benzodiazepinedione. More preferably, the substituted 1,4-
benzodiazepine-2,5-diones disclosed and claimed in U.S.Pat.No. 5,663,166, are used
as glycoprotein IIb/IIIa binding moieties in the compounds of the invention. Most

preferably, substituted 1,4-benzodiazepine-2,5-diones corresponding to the formulae set forth below are used as glycoprotein IIb/IIIa binding moieties in the compounds of the invention.

In one embodiment, the invention provides a compound having a formula:




5

where R^1 is C_1 - C_8 lower alkyl, R^2 , R^3 , R^4 , R^5 , and R^6 are each independently H, C_1 - C_8 lower alkyl, substituted C_1 - C_8 alkyl, aryl, substituted aryl, or a combination thereof; L^1 is a linking moiety; Q is a positively charged nitrogen-containing moiety; and M is a metal ion chelator.


10 As defined herein, "substituted C_1 - C_8 alkyl" means an alkyl of the designated length substituted with a hydroxyl group, an ether, a thioether, a C_1 - C_8 branched hydrocarbon, a C_1 - C_8 straight chain hydrocarbon, an amine, a primary alkylamine, a secondary alkylamine, a primary arylamine, a secondary arylamine, a primary alkylsilicate, a secondary alkylsilicate, a tertiary alkylsilicate, and the like. In
 15 accordance with the invention, "aryl" may be saturated or unsaturated and may optionally be a heterocycle. A "substituted aryl" of the invention means an aryl which may optionally be a heterocycle and which is substituted at one or more positions with a hydroxyl group, an ether, a thioether, a C_1 - C_8 branched hydrocarbon, a C_1 - C_8 straight chain hydrocarbon, an amine, a primary alkylamine, a secondary
 20 alkylamine, a primary arylamine, a secondary arylamine, a nitro group, a halogen, a sulfonic acid, an alkylsulfonyl, a sulfonamide, and the like.

In another embodiment, the invention provides a compound having a formula:




- where R^2 is C_1 - C_8 lower alkyl, $R^1, R^3, R^4, R^5,$ and R^6 are each independently H, C_1 - C_8 lower alkyl, substituted C_1 - C_8 alkyl, aryl, substituted aryl, or a combination thereof;
- 5 L^1 is a linking moiety; Q is a positively charged nitrogen-containing moiety; and M is a metal ion chelator.

In another embodiment, the invention provides a compound having a formula:




- where R^3 is C_1 - C_8 lower alkyl; $R^1, R^2, R^4, R^5,$ and R^6 are each independently H, C_1 - C_8 lower alkyl, substituted C_1 - C_8 alkyl, aryl, substituted aryl, or a combination thereof;
- 10 L^1 is a linking moiety; Q is a positively charged nitrogen-containing moiety; and M is a metal ion chelator.

In another embodiment, the invention provides a compound having a formula:



where R^4 is C_1 - C_8 lower alkyl; R^1, R^2, R^3, R^5 , and R^6 are each independently H, C_1 - C_8 lower alkyl, substituted C_1 - C_8 alkyl, aryl, substituted aryl, or a combination thereof; L^1 is a linking moiety; Q is a positively charged nitrogen-containing moiety; and M is a metal ion chelator.


5 In another embodiment, the invention provides a compound having a formula:



where R^5 is C_1 - C_8 lower alkyl; R^1, R^2, R^3, R^4 , and R^6 are each independently H, C_1 - C_8 lower alkyl, substituted C_1 - C_8 alkyl, aryl, substituted aryl, or a combination thereof;

10 L^1 is a linking moiety; Q is a positively charged nitrogen-containing moiety; and M is a metal ion chelator.

In another embodiment, the invention provides a compound having a formula:



15 where R^6 is C_1 - C_8 lower alkyl; R^1, R^2, R^3, R^4 , and R^5 are each independently H, C_1 - C_8 lower alkyl, substituted C_1 - C_8 alkyl, aryl, substituted aryl, or a combination thereof; L^1 is a linking moiety; Q is a positively charged nitrogen-containing moiety; and M is a metal ion chelator.

20 In each of the formulae set forth above, linking moiety L^1 is a bivalent radical containing from about 3 to about 9 methylene groups, or L^1 may be a bivalent radical having a length equivalent to from about 3 to about 9 methylene groups. Preferably, L^1 has a length equivalent to from about 4 to about 6 methylene groups. More preferably, L^1 has a length equivalent to about 5 methylene groups. L^1 preferably

contains one or more sp^2 or sp atoms and thus is constrained. In accordance with the invention, L^1 may contain one or more alkene, alkyne, aryl, heterocycle groups, or a functional group or groups containing N, O, or S. Preferably, L^1 comprises a ketone, sulfoxide, secondary amine, amide, ureido, carbamate, sulfonamide, or sulfone. More preferably, L^1 comprises a thioether. Most preferably, L^1 comprises an ether, in particular, an alkylether such as a methylether.

Positively charged moiety Q contains one or more nitrogen atoms and has a pK_b sufficiently high that said atoms are at least 10% positively charged at physiological pH. In accordance with the invention, Q may comprise one or more primary, secondary, tertiary, or quaternary amines or imines either isolated or conjugated with other nitrogen atoms. Alternatively, Q may be a saturated or unsaturated (including aromatic) heterocyclic group, provided that said group bears a positive charge at physiological pH.


In accordance with the invention Q may be selected from but is not limited to such groups as: amino, imino, amidino, aminomethyleneimino, aminomethyleneamino, iminomethylamino, guanidino, N^G -aminoguanidino, alkylamino, dialkylamino, trialkylamino, alkylideneamino, pyranyl, pyrrolyl, imidazolyl, pyrazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, indoliziny, isoindolyl, 3H-indolyl, indolyl, 1H-indazolyl, purinyl, 4H-quinoliziny, isoquinolyl, quinolyl, phthalazinyl, naphthyridinyl, quinoxaliny, quinazoliny, cinnoliny, pteridinyl, 4aH-carbazolyl, carbazolyl, b-carboliny, phenanthridinyl, acridinyl, phenanthroliny, phenazinyl, phenarsazinyl, phenothiazinyl, pyrroliny, imidazolidinyl, imidazoliny, pyrazolidinyl, pyrazoliny, piperidyl, piperazinyl, indoliny, isoindoliny, quinuclidiny, morpholiny, 1,3-diazacyclohex-4-ene, and multiples thereof. Optionally, any of the nitrogen-containing heterocycles set forth above may be substituted with amino, imino, amidino, aminomethyleneamino, iminomethylamino, guanidino, N^G -amino-guanidine, alkylamino, dialkylamino, trialkylamino, or alkylidene-amino groups. Preferably, Q is a amidino or substituted amidino group.

Methods for making substituted glycoprotein IIb/IIIa receptor binding benzodiazepinediones are disclosed in U.S.Pat.Nos. 5,403,836; 5,493,020; 5,565,449; 5,663,166; 5,674,863; 5,674,865; 5,705,890; and 5,716,951 and in Example 1 below.

Methods for making substituted glycoprotein IIb/IIIa receptor binding benzodiazepines are disclosed in Ku *et al.*, *supra*.


The compounds of the invention may comprise any metal ion chelator. The metal ion chelator may be covalently linked to the substituted benzodiazepine at any position of the benzodiazepine scaffold, so long as the presence of the chelator does not substantially interfere with the compound's ability to bind to the glycoprotein IIb/IIIa receptor. By "substantially interfere" is meant that the compound retains some potency for inhibition of human platelet aggregation, as defined above.

For example, the compounds of the invention may comprise a metal ion chelator having a formula:




where (pgp)^S is hydrogen or a thiol protecting group and (aa) is any α- or β-amino acid not comprising a thiol group. In a preferred embodiment, the amino acid is glycine. Methods for making such a metal ion chelator are set forth in U.S.Pat.Nos. 5,654,272; 5,681,541; 5,788,960; and 5,811,394.

Alternatively, the compound of the invention may comprise a metal ion chelator of capable of forming an electrically neutral complex with the metal ion, as set forth in U.S.Pat.Nos. 5,720,934; 5,776,428; and 5,780,007; in allowed USSNs 08/467,791, 08/468,964; and 08/170,299; and in USSN 07/871,282. Such chelators include but are not limited to:




wherein X = H or a protecting group;
(amino acid) = any amino acid;

25




wherein X = H or a protecting group;

(amino acid) = any amino acid;



wherein each R can be independently H, CH₃ or C₂H₅; each (pgp)^s can be independently a thiol protecting group or H; m, n and p are independently 2 or 3; A is linear C₁-C₈ alkyl, substituted linear C₁-C₈ alkyl, cyclic C₃-C₈ alkyl, substituted cyclic C₃-C₈ alkyl, aryl, substituted aryl, or a combination thereof; and X is benzodiazepine; and

10



15 wherein each R is independently H, CH₃ or C₂H₅; m, n and p are independently 2 or 3; A is linear C₁-C₈ alkyl, substituted linear C₁-C₈ alkyl, cyclic C₃-C₈ alkyl, substituted cyclic C₃-C₈ alkyl, aryl, substituted aryl, or a combination thereof; V is H or CO-benzodiazepine; R' is H or benzodiazepine; provided that when V is H, R' is benzodiazepine and when R' is H, V is CO-benzodiazepine. In accordance with the


20 invention, the substituted derivatives in the bisamide, bithiol formulae are defined as set forth above.

Alternatively, the compound of the invention may comprise a metal ion chelator having a formula selected from the group consisting of:

25 diethylenetriaminepentaacetic acid (DTPA);
 a derivative of DTPA having a formula
 $(\text{HOOCCH}_2)_2\text{N}(\text{CR}_2)(\text{CR}_2)\text{N}(\text{CH}_2\text{COOH})(\text{CR}_2)(\text{CR}_2)\text{N}(\text{CH}_2\text{COOH})_2$;

where each R is independently H, C₁ to C₄ alkyl, or aryl and one R is covalently linked to a bivalent linker;


30 ethylenediaminetetraacetic acid (EDTA);
 a derivative of EDTA having a formula



where each R is independently H, C₁ to C₄ alkyl, or aryl and one R is covalently linked to a bivalent linker;


1,4,7,10-tetraazacyclododecanetetraacetic acid and derivatives thereof;

5 a metal ion chelator having a formula:




where n is an integer that is 2 or 3 and where each R is independently H, C₁ to C₄ alkyl, or aryl and one R is covalently linked to the benzodiazepine derivative, and desferrioxamine.

15 More preferably, the compounds of the invention comprise a monoamine, diamide, single thiol containing metal ion chelator such as those set forth in commonly assigned copending USSN 08/253,973. Exemplary of such metal ion chelators are chelators having the formulae:




20

and



wherein n, m and p are each integers that are independently 0 or 1; each R' is independently H, lower alkyl, C₂-C₄ hydroxyalkyl, or C₂-C₄ alkoxyalkyl, and each R is independently H or R'', where R'' is a substituted C₁-C₈ alkyl not comprising a thiol group, a unsubstituted C₁-C₈ alkyl, an unsubstituted phenyl, or a substituted phenyl not comprising a thiol group, and one R or R' is L², where L² is a bivalent linker moiety linking the metal chelator to the glycoprotein IIb/IIIa receptor-binding benzodiazepine and wherein when one R' is L², NR'₂ is an amine. In this embodiment, L² may be a C₁-C₆ linear alkyl group, a branched chain alkyl group, a cyclic alkyl group, a carboxylic ester, a carboxamide, a sulfonamide, an ether, a thioether, an amine, an alkene, an alkyne, a 1,2-linked, optionally substituted, benzene ring, a 1,3-linked, optionally substituted, benzene ring, a 1,4-linked, optionally substituted, benzene ring, or an amino acid, or a combination thereof. In this embodiment, R'' may be a C₁-C₆ linear alkyl group; a branched alkyl group; a cyclic alkyl group; a -C_qOC_r-, -C_qNHC_r- or -C_qSC_r- group, where q and r are integers each independently 1 to 5 wherein the sum of q + r is not greater than 6; (C₁-C₆) alkyl-X, where X is a hydroxyl group, a substituted amine, a guanidine, an amidine, a substituted thiol group, or a carboxylic acid, ester, phosphate, or sulfate group; a phenyl group or a phenyl group substituted with a halogen, a hydroxyl group, a substituted amine, a guanidine group, an amidine group, a substituted thiol, an ether, a phosphate, a sulfate; an indole group; a C₁-C₆ heterocyclic group containing 1 to 3 nitrogen, oxygen or sulfur atoms, or a combination thereof. In accordance with the invention, the substituted derivatives in the monoamine, diamide, thiol-containing chelator formulae are defined as set forth above.


Most preferably, the compounds of the invention comprise a metal ion chelator comprising a single thiol-containing group of formula:



wherein A is H, HOOC-, H₂NOC-, -NHOC-, -OOC-, R^e₂NOC-, or R^d; B is H, SH, -NHR^c, -N(R^c)- or R^d; Z is H or R^d; X is SH, -NHR^c, -N(R^c)- or R^d; R^a, R^b, R^c and R^d are independently H, straight chain C₁-C₈ alkyl, branched chain C₁-C₈ alkyl, or cyclic C₃-C₈ alkyl; n is 0, 1 or 2; R^e is C₁-C₄ alkyl, an amino acid, or a peptide comprising 2 to about 10 amino acids; and: (1) where B is -NHR^c or -N(R^c)-, X is SH and n is 1 or 2; (2) where X is -NHR^c or -N(R^c)-, B is SH and n is 1 or 2; (3) where B is H or R^d, A is HOOC-, H₂NOC-, -NHOC-, or -OOC-, X is SH and n is 0 or 1; (4) where A is H or


R^d , then where B is SH, X is $-NHR^c$ or $-N(R^c)-$ and where X is SH, B is $-NHR^c$ or $-N(R^c)-$ and n is 1 or 2; (5) where X is H or R^d , A is $HOOC-$, H_2NOC- , $-NHOC-$, or $-OOC-$ and B is SH; (6) where Z is methyl, X is methyl, A is $HOOC-$, H_2NOC- , $-NHOC-$, or $-OOC-$ and B is SH and n is 0; and (7) where B is SH, X is not SH and
 5 where X is SH, B is not SH.

In accordance with the invention, a metal ion chelator comprising a single thiol-containing group may have the formula:



wherein $(\text{amino acid})^1$ and $(\text{amino acid})^2$ are each independently any primary α - or β -
 10 amino acid that does not comprise a thiol group, Z^1 is selected from the group consisting of cysteine, homocysteine, isocysteine, penicillamine, 2-mercaptoethylamine, 2-mercaptopropylamine, 2-mercapto-2-methylpropylamine, and 3-mercaptopropylamine, and R^1 is lower (C^1-C^4) alkyl, or R^1-CO is an amino acid, a peptide, or (aa)-peptide; wherein when Z^1 is cysteine, homocysteine, isocysteine or penicillamine, Z^1 comprises a
 15 carbonyl group covalently linked to a hydroxyl group, a NR^3R^4 group, wherein each of R^3 and R^4 are independently H, a bond, lower (C^1-C^4) alkyl, an amino acid or a peptide comprising from 2 to 10 amino acids; and

Alternatively, a metal ion chelator comprising a single thiol-containing group may have the formula:



wherein $(\text{amino acid})^1$ and $(\text{amino acid})^2$ are each independently any primary α - or β -
 amino acid that does not comprise a thiol group Y is selected from the group consisting of cysteine, homocysteine, isocysteine, penicillamine, 2-mercaptoacetate, 2-mercaptopropionate, 2-mercapto-2-methylpropionate, 3-mercaptopropionate, and R^2 is
 25 H, a bond, lower (C^1-C^4) alkyl, and NHR^2 is an amino acid, a peptide, or (aa)-peptide; wherein when Y is cysteine, homocysteine, isocysteine or penicillamine, Y comprises an amino group covalently linked to $-H$, an amino acid, a peptide, or (aa)-peptide.

Any naturally occurring, modified, substituted, or altered amino acid may be used in the single-thiol chelators of the invention. As used herein, the term "modified, substituted, or altered α - or β - amino acid" includes, without limitation, penicillamine
 30 (Pen); 6-aminocaproic acid (Aca); homolysine (Hly); L-{S-(3-aminopropyl)cysteine} (Apc); D-amino acids such as D-phenylalanine (F_D), D-tryptophan (W_D), D-tyrosine (Y_D),

and the like; L-(4-chlorophenyl)alanine (Cpa); 4-amino-tetrahydrothiopyran-4-carboxylic acid (Thp); 2-naphthylalanine (Nal); D-2-naphthylalanine (D-Nal); dipropylglycine (Dpg); norleucine (Nle); homocysteine (Hcy); homohomocysteine (Hhc); aminoisobutyric acid (Aib); 2-aminoindan-2-carboxylic acid (Ain); 4-amino-cyclohexylalanine (Achxa); 4-aminomethyl-phenylalanine (Amf); S-(2-aminoethyl)cysteine (Aec); is O-(3-aminopropyl)serine (Aps); 2-aminobutyric acid (Abu); norvaline (Nva); 4-amidino-phenylalanine (Amp), 2-amino suberic acid (Asu), and the like. In accordance with the invention, the carboxyl terminal amino acids of the chelators of the invention may be in carboxylic acid form or in amidated form.

10 For example, suitable metal ion chelators may have any of the following formulae:

(amino acid)¹-(amino acid)²-cysteine-,
 (amino acid)¹-(amino acid)²-isocysteine-,
 (amino acid)¹-(amino acid)²-homocysteine-,
 15 (amino acid)¹-(amino acid)²-penicillamine-,
 (amino acid)¹-(amino acid)²-2-mercaptoethylamine-,
 (amino acid)¹-(amino acid)²-2-mercaptopropylamine-,
 (amino acid)¹-(amino acid)²-2-mercapto-2-methylpropylamine-,
 (amino acid)¹-(amino acid)²-3-mercaptoethylamine-,

20 wherein the chelator is attached to either a substituted benzodiazepine or a linker group *via* a covalent bond with the carboxyl terminus of the chelator or a side chain on one of the amino acid groups.

Other suitable metal ion chelators include those selected from the group consisting of:

25 -cysteine-(amino acid)-(α,β- or β,γ-diamino acid);
 -isocysteine-(amino acid)-(α,β- or β,γ-diamino acid);
 -homocysteine-(amino acid)-(α,β- or β,γ-diamino acid);
 -penicillamine-(amino acid)-(α,β- or β,γ-diamino acid);
 2-mercaptoacetic acid-(amino acid)-(α,β- or β,γ-diamino acid);
 30 2- or 3-mercaptopropionic acid-(amino acid)-(α,β- or β,γ-diamino acid);
 2-mercapto-2-methylpropionic acid-(amino acid)-(α,β- or β,γ-diamino acid);

wherein the metal ion chelator is attached to either a substituted benzodiazepine or a linker group *via* a covalent bond with the amino terminus of the chelator or a side chain on one of the amino acid groups.

For example, the compounds of the invention may include metal ion chelators
5 having a formula selected from the group consisting of: –Gly–Gly–Cys, –Gly–Gly–
Cys.amide, Gly–Gly–Cys–, Cys–Gly–Gly–, –Gly–Gly–Gly–Cys (SEQ ID.NO:1), –
Gly–Gly–Gly–Cys.amide (SEQ. ID.NO:1), Arg–Gly–Cys–, –(ε-Lys)–Gly–Cys–, –(δ-
Orn)–Gly–Cys–, –(γ-Dab)–Gly–Cys–, and –(β-Dap)–Lys–Cys–, and the like. (In these
10 formulae, it will be understood that ε-Lys represents a lysine residue in which the ε-
amino group, rather than the typical α-amino group, is covalently linked to the carboxyl
group of the adjacent amino acid to form a peptide bond; δ-Orn represents an ornithine
residue in which the δ-amino group, rather than the typical α-amino group, is covalently
linked to the carboxyl group of the adjacent amino acid to form a peptide bond; γ-Dab
15 represents a 2,4-diaminobutyric acid residue in which the γ-amino group is covalently
linked to the carboxyl group of the adjacent amino acid to form a peptide bond; and β-
Dap represents a 1,3-diaminopropionic acid residue in which the β-amino group is
covalently linked to the carboxyl group of the adjacent amino acid to form a peptide
bond. Other abbreviations for amino acids are conventional. The designation
“Cys.amide” represents the amidated form of the residue cysteine.)

20 Methods for making metal ion chelators of the most preferred embodiment are
set forth in U.S.Pat.Nos. 5,443,815; 5,807,537; 5,814,297; and 5,866,097 and in USSNs
08/236,402; 08/253,678; 08/253,973; and 08/582,134.

Those of skill will recognize that most metal ions may be chelated to the above-
mentioned metal ion chelators. Any metal ion capable of generating a signal label may
25 be chelated to the benzodiazepine derivative compound of the invention, thus forming
a metal ion complex with the compound of the invention. Suitable metal ions include
radioactive metal ions, fluorescent metal ions, paramagnetic metal ions, heavy metals,
rare earth ions suitable for use in computerized tomography, and the like. Radioactive
metal ions or radionuclides are preferred. More preferably, γ-emitting radionuclides
30 such as ⁶⁷Cu, ⁶⁸Ga, ¹¹¹In, and ^{99m}Tc, are used in the methods of the invention. Most
preferably, complexes formed between, ^{99m}Tc and the compounds of the invention are
used to image thrombi.

The metal ion chelator associates with the metal ion to form a chelate, and the atoms of a chelator are commonly known as "ligands". In the chelating art, ligands are atoms capable of donating electrons to form the coordinate bonds of the chelate. In accordance with the invention, when the metal ion is ^{99m}Tc , the chelate is termed a
5 "99mTc-chelate". ^{99m}Tc is a thiophilic metal, and thus the ^{99m}Tc -chelates of the invention preferably contain at least one sulfur ligand bound via a coordinate covalent bond to the ^{99m}Tc .

Complexes and chelates of the invention may be formed using known methods. For example, a salt of ^{99m}Tc pertechnetate may be reacted with the compound
10 in the presence of a reducing agent such as dithionite ions, stannous ions or ferrous ions. In this method, the most preferred reducing agent is stannous chloride. Alternatively, complexes and chelates may be formed by ligand exchange, wherein the compound of the invention is reacted with a pre-formed labile complex of ^{99m}Tc and another compound known as a transfer ligand. In this process, any transfer ligand may be used,
15 for example, tartrate, citrate, gluconate, glucoheptonate, or mannitol.

Thrombus imaging agents produced using the compounds of the invention are preferably administered intravenously to a living mammal, as pharmaceutical compositions. The compound of the invention is formulated as a sterile, pyrogen-free, parenterally acceptable aqueous solution which may optionally be supplied in
20 lyophilized form and be reconstituted by the user.

The pharmaceutical composition of the invention comprise a compound of the invention in combination with a pharmaceutically acceptable diluent or a carrier such as species appropriate albumin. As used herein, a "pharmaceutically acceptable diluent or carrier" may include any and all solvents, dispersion media, antibacterial
25 and antifungal agents, isotonic agents, enzyme inhibitors, stabilizers, and the like. The use of such media and agents for pharmaceutically active substances is well known in the art. For example, Sodium Chloride Injection and Ringer's Injection are commonly used as diluents. The preparation of such parenterally acceptable solutions, having due regard to pH, isotonicity, stability, and the like, is within the skill in the
30 art.

The compounds and compositions of the invention may be provided as components of kits which may include buffers, additional vials, instructions for use,

and the like. The kit of the invention comprises a sealed vial containing a predetermined quantity of the compound, and optionally, when the metal ion is technetium-99m, a reducing agent. An appropriate amount of a transfer ligand such as tartrate, citrate, gluconate, glucoheptonate or mannitol, for example, can also be included in the kit. The components of the kit may be in liquid, frozen or dry form. Preferably, kit components are provided in lyophilized form.

In accordance with the method of this invention, imaging agents produced from pharmaceutical compositions comprising the benzodiazepine derivative compounds of the invention are preferably administered intravenously in a single unit dose, either totally as a bolus or partly as a bolus followed by infusion over 1-2 hours.. The amount of solution to be injected at unit dosage is from about 0.01 mL to about 10 mL, containing about 0.01 mCi to about 100 mCi of radioactivity, preferably from about 1 mCi to about 20 mCi.. The amount of the compound in the unit dose may range from about 0.1 to about 10 mg/kg body weight, After intravenous administration, the thrombus site is monitored, for example, by radioimaging *in vivo*.

The following examples are shown by way of illustration and not by way of limitation.

EXAMPLE 1**Synthesis Of 1-[(carboxyglycyl-glycyl-glycyl-cysteinamide)methyl]-4-(2-carboxyethyl)-7-[(4-amidinophenyl)methyl]-3,4-dihydro-1H-1,4-benzodiazepine-2,5-dione**

Synthesis of an exemplary benzodiazepinedione imaging agent is set forth below.

A. N-Boc-5-hydroxyanthranilic acid [1]

5-Hydroxyanthranilic acid (100 g, 0.65 mol) was transferred into a 5 liter 3-necked round bottom flask equipped with a mechanical stirrer. A solution of saturated sodium carbonate (1.5 liters) was added to the reaction flask with stirring. After carbon dioxide evolution had subsided, di-t-butyl dicarbonate (156.8 g, 0.72 mol) in 1.5 liters of tetrahydrofuran (THF) was added to the reaction vessel which was stirred at a rate which insured complete mixing of the resulting biphasic mixture. The reaction mixture was stirred at room temperature for 24 hours at which time 1.0 liters of ethyl ether was added and the mixture transferred to a separatory funnel. The aqueous layer was extracted with an additional 1.0 liters of ethyl ether and brought to pH = 3.0 with 2 M H₃PO₄. Product was extracted from the aqueous solution with ethyl acetate (3 x 1.0 liters). The combined organics were washed with a saturated NaCl solution, dried over Na₂SO₄, filtered and concentrated *in vacuo* to yield N-Boc-5-hydroxyanthranilic acid (153 g, 92.5 % yield).

B. N-Boc-5-benzyloxyanthranilic acid, benzyl ester [2]

Sodium hydride (95%, 36.2 g, 1.51 mol) was placed into a dry 5 liter 3-necked round bottom flask under an atmosphere of argon. Anhydrous dimethylformamide (DMF) (2.0 liters) was added via canula followed by the careful addition of N-Boc-5-hydroxyanthranilic acid (150 g, 0.59 mol). The reaction mixture was cooled with an ice/water bath and benzyl bromide (148 mL, 1.24 mol) was added via syringe keeping the reaction temperature below 50°C. After addition was complete, the reaction mixture was stirred at 45°C – 50°C for 6 hours. At this time additional benzyl bromide (35 mL, 0.29 mol) was added and the reaction continued at 45°C – 50°C for an additional 2 hours. Acetic acid (20 mL) was carefully added and the reaction

mixture was transferred to a round bottom flask and concentrated to a volume of approximately 400 mL. Ethyl acetate (1.0 liters) was added and the resulting solution was decanted from any solids present. The flask was rinsed with additional ethyl acetate (2 x 500 mL), decanting after each rinse. The combined organics were washed with water (1.0 liter) and saturated NaCl (500 mL). The organics were filtered and concentrated *in vacuo* to yield crude N-Boc-5-benzyloxyanthranilic acid, benzyl ester as a reddish brown syrup. The crude product was transferred to boiling hexanes (3 liters) and refluxed an additional 10 minutes. The solution was filtered while still hot and allowed to cool for 48 hours to yield 72 g of product (28 % yield).

10

C. 5-Benzyloxyanthranilic acid, benzyl ester, hydrochloride [3]

N-Boc-5-benzyloxyanthranilic acid, benzyl ester (70 g, 161 mmol) was added to a 1.4 M HCl/ethyl acetate solution (prepared by the addition of methanol to acetyl chloride and subsequent dilution with ethyl acetate). The reaction mixture was stirred at room temperature for 21 hours. After cooling to 0°C, the reaction was gently stirred for an additional 2 hours. The crystalline product was filtered off and washed with 50 ml of cold ethyl acetate. Trace solvents were removed under high vacuum to yield 5-benzyloxyanthranilic acid, benzyl ester, hydrochloride (53.4 g, 86 % yield).

15

20 D. N-(Carbo-t-butoxymethyl)-5-benzyloxyanthranilic acid, benzyl ester [4]

A solution of saturated sodium bicarbonate (1.0 liter) was placed in a 4 liter Erlenmeyer flask along with 1.0 liter of ethyl acetate. The biphasic mixture was stirred at a rate that insured mixing and 5-benzyloxyanthranilic acid, benzyl ester, hydrochloride (50.0 g, 135 mmol) was added portionwise to the stirred mixture. After addition was complete, the mixture was stirred an additional 15 minutes. The layers were partitioned in a separatory funnel and the aqueous layer was extracted with ethyl acetate (500 mL). The combined organics were dried over MgSO₄, filtered, and concentrated *in vacuo* to yield the free base, which was dissolved in anhydrous DMF (700 mL) under an atmosphere of argon. 2,6-lutidine (20.0 mL, 172 mmol) was added to the solution followed by the addition of t-butyl bromoacetate (29.0 mL, 196 mmol). The reaction mixture was stirred at 70°C under an atmosphere of argon for 48 hours. The DMF was removed on a rotary evaporator under high vacuum and the

25

30

crude product residue was partitioned between ethyl acetate (1.0 liter) and water (500 mL). The organic layer was washed with saturated NaCl (250 mL) and dried over Na₂SO₄. The solution was filtered and concentrated *in vacuo* to yield crude product as a light brown solid. The product was recrystallized from 7% ethyl acetate/hexanes to yield N-(carbo-t-butoxymethyl)-5-benzyloxyanthranilic acid, benzyl ester (46.4 g, 79 % yield).

E. N-(Carbo-t-butoxymethyl)-5-hydroxyanthranilic acid [5]

N-(Carbo-t-butoxymethyl)-5-benzyloxyanthranilic acid, benzyl ester (45.0 g, 101 mmol) was dissolved in 1:1 THF/ethyl acetate (1200 mL) in a 2 liter round bottom flask. The atmosphere was flushed with argon and 10% Pd/C (4.0 g) was added. The reaction atmosphere was replaced with hydrogen gas (4 purge-fill cycles) and the reaction mixture stirred under a balloon of hydrogen for 23 hours. The atmosphere was replaced with argon and the reaction mixture filtered through a pad of Celite, washing the Celite pad with methanol (250 mL). The solvents were removed *in vacuo* and the resulting yellow solid placed under high vacuum overnight to yield N-(carbo-t-butoxymethyl)-5-hydroxyanthranilic acid (27.1 g, 100% yield).

F. N-(Carbobenzyloxymethyl)-3-aminopropionic acid, ethyl ester [6]

Ethyl acrylate (24.4 mL, 225 mmol) and glycine, benzyl ester, p-toluenesulfonate (50.0 g, 148 mmol) were combined in a 250 mL round bottom flask. With stirring, triethylamine (24.8 mL, 178 mmol) was added via syringe and the reaction mixture was stirred at room temperature for 22 hours. The reaction mixture was partitioned between ethyl acetate (660 mL) and 10% aqueous Na₂CO₃ (300 mL). The organics were washed with water (100 mL) and saturated NaCl (100 mL). The organics were dried over MgSO₄, filtered and concentrated *in vacuo* followed by pumping under high vacuum to yield N-(carbobenzyloxymethyl)-3-aminopropionic acid, ethyl ester (39.3 g, 73% yield) as a yellow oil.

30

F. 1-(Carbo-t-butoxymethyl)-4-(2-carboethoxyethyl)-7-hydroxy-3,4-dihydro-1H-1,4-benzodiazepine-2,5-dione [7]

N-(Carbo-t-butoxymethyl)-5-hydroxyanthranilic acid (26.7 g, 100 mmol) was placed in a dry 2 liter round bottom flask. The reaction atmosphere was flushed with argon and N-(carbobenzyloxymethyl)-3-aminopropionic acid, ethyl ester (29.0 g, 109 mmol) in anhydrous DMF (500 mL) was added, followed by the addition of O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HATU reagent, 39.9 g, 105 mmol). Triethylamine (42.0 mL, 301 mmol) was added and the reaction mixture was stirred at room temperature under a balloon of argon for 16 hours. The DMF was removed *in vacuo* on a rotary evaporator and the residue partitioned between ethyl acetate (1.0 liter) and saturated NaHCO₃ (500 mL). The organics were washed with water (500 mL), saturated NaCl (100 mL) and dried over MgSO₄. The organics were filtered, the volatiles removed *in vacuo* on a rotary evaporator and the residual oil pumped on under high vacuum to yield an oil. This oil was taken up in 9:3 ethyl acetate/methanol (1200 mL) and placed under an atmosphere of argon gas. 10% Pd/C (4.0 g) was added and the reaction atmosphere replaced with hydrogen gas (4 purge-fills). The reaction mixture was stirred under a balloon of hydrogen for 45 hours. The reaction atmosphere was replaced with argon and the suspension filtered through a pad of Celite, which was washed with an additional 300 mL of methanol. The volatiles were removed *in vacuo* and the residue was taken up in a minimum of dichloromethane and chromatographed on silica gel, eluting the column with 1:1 ethyl acetate/hexanes. Fractions containing pure product (R_f = 0.17 in 1:1 ethyl acetate/hexanes) were combined and the solvents removed *in vacuo* to yield 1-(carbo-t-butoxymethyl)-4-(2-carboethoxyethyl)-7-hydroxy-3,4-dihydro-1H-1,4-benzodiazepine-2,5-dione as a white solid (20.2 g, 50% yield).

G. 1-(Carbo-t-butoxymethyl)-4-(2-carboethoxyethyl)-7-[(4-cyanophenyl)methyl]-3,4-dihydro-1H-1,4-benzodiazepine-2,5-dione [8]

1-(Carbo-t-butoxymethyl)-4-(2-carboethoxyethyl)-7-hydroxy-3,4-dihydro-1H-1,4-benzodiazepine-2,5-dione (19.5 g, 48 mmol), α -bromo-*p*-tolunitrile (11.3 g, 58 mmol), and potassium carbonate (9.0 g, 65 mmol) were combined in a round bottom flask. Anhydrous DMF (300 mL) was added and the reaction mixture was stirred at 40°C for 4 days. The reaction mixture was filtered and the filtrate was concentrated *in*

vacuo on a rotary evaporator. The residue was partitioned between ethyl acetate (500 mL) and water (100 mL). The organics were washed with saturated NaCl (50 mL) and dried over Na₂SO₄. The volatiles were removed *in vacuo* on a rotary evaporator and the residue was chromatographed on silica gel, eluting the column with 5:6 ethyl acetate/hexanes. Fractions containing pure product (R_f = 0.17, 5:6 ethyl acetate/hexanes) were combined and the solvents removed *in vacuo* on a rotary evaporator to yield 1-(carbo-t-butoxymethyl)-4-(2-carboethoxyethyl)-7-[(4-cyanophenyl)methyl]-3,4-dihydro-1H-1,4-benzodiazepine-2,5-dione (20.7 g, 83% yield).

10

H. 1-(Carbo-t-butoxymethyl)-4-(2-carboethoxyethyl)-7-[(4-amidinophenyl)methyl]-3,4-dihydro-1H-1,4-benzodiazepine-2,5-dione, acetate [9]

1-(Carbo-t-butoxymethyl)-4-(2-carboethoxyethyl)-7-[(4-cyanophenyl)methyl]-3,4-dihydro-1H-1,4-benzodiazepine-2,5-dione (16.0 g, 31 mmol) was placed in a dry 3-necked flask equipped with an inlet tube for gas dispersion and an outlet tube connected to a trap containing 1:1 2M NaOH/Clorox bleach. The flask was flushed with argon gas and anhydrous pyridine (90 mL) was added followed by the addition of triethylamine (70 mL). The resulting solution was saturated with hydrogen sulfide gas. The inlet and outlet tubes were removed and the reaction mixture was heated at 55°C – 60°C for 21 hours. The reaction mixture was purged with argon and the volatiles removed *in vacuo* on a rotary evaporator. The residue was taken up in 5:4 dichloromethane/toluene (450 mL) and this was also removed *in vacuo* on a rotary evaporator. The treatment with dichloromethane/toluene was repeated once more. The residue was taken up in acetone (300 mL) and iodomethane (5.2 mL, 84 mmol) was added via syringe. The reaction mixture was stirred and heated at 60°C – 65°C for 5.5 hours. The reaction mixture was cooled and the volatiles removed *in vacuo* on a rotary evaporator. The residue was taken up in anhydrous methanol (200 mL) under an atmosphere of argon and ammonium acetate (9.25 g, 120 mmol) was added. The reaction mixture was stirred at room temperature under an atmosphere of argon for 21 hours. The volatiles removed *in vacuo* on a rotary evaporator and the residue was taken up in acetonitrile (200 mL) and filtered through a sintered glass funnel. The reaction vessel was rinsed with additional acetonitrile (100 mL) which was also

filtered through the sintered glass funnel. The filtrate was concentrated *in vacuo* on a rotary evaporator and the residue pumped on under high vacuum to yield 1-(carbo-t-butoxymethyl)-4-(2-carboethoxyethyl)-7-[(4-amidinophenyl)methyl]-3,4-dihydro-1H-1,4-benzodiazepine-2,5-dione, acetate (18.2 g, 99% yield).

5

I. 1-(Carboxymethyl)-4-(2-carboethoxyethyl)-7-[(4-amidinophenyl)methyl]-3,4-dihydro-1H-1,4-benzodiazepine-2,5-dione, hydrochloride [10]

1-(carbo-t-butoxymethyl)-4-(2-carboethoxyethyl)-7-[(4-amidinophenyl)methyl]-3,4-dihydro-1H-1,4-benzodiazepine-2,5-dione, acetate (17.7 g, 30 mmol) was placed in a dry round bottom flask and 4M HCl/dioxane was added via syringe. The reaction mixture was stirred at room temperature for 1.5 hours and then added dropwise to a stirred solution of anhydrous ethyl ether (1.0 liter). After addition was complete, the resulting suspension was stirred an additional 15 minutes and filtered under a blanket of argon gas. The collected solid was washed with anhydrous ethyl ether, transferred to a round bottom flask, and dried under high vacuum to yield 1-(carboxymethyl)-4-(2-carboethoxyethyl)-7-[(4-amidinophenyl)methyl]-3,4-dihydro-1H-1,4-benzodiazepine-2,5-dione, hydrochloride as a white solid (14.2 g, 93 % yield). ¹H NMR (CD₃OD): 1.25 ppm, (t, 3H); 2.70 ppm, (m, 2H); 3.70 ppm – 4.21 ppm, (m, 4H); 4.12 (q, 2H); 4.50 ppm, (s, 2H); 5.39 ppm, (s, 2H); 7.20 ppm – 7.40 ppm (m, 3H); 7.71 ppm (d, 2H); 7.83 ppm (d, 2H).

20

J. Fmoc-Glycyl-glycyl-glycyl-S-Tritylcysteinyl-Rink amide resin [11]

Fmoc-Rink amide resin (12.5 g, 0.66 mmol/g, 8.25 mmol) was sequentially coupled to N-Fmoc-S-tritylcysteine, Fmoc-glycine, Fmoc-glycine, Fmoc-glycine, and Fmoc-glycine using the following solid-phase peptide synthesis protocol: The N-terminal Fmoc group was removed by treatment of the resin with 20% piperidine/DMF (2 times, 5 min. then 15 min.). The resin was washed with DMF (4 x 1 min.). The resulting resin-supported N-terminal free amine was suspended in DMF and reacted with N-Fmoc-S-tritylcysteine (13.7 g, 23.4 mmol), which was preactivated with a 0.45M solution of 1:1 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate/N-hydroxybenzotriazole (HBTU/HOBt) in DMF (52 mL, 23.4 mmol) and diisopropylethylamine (8.3 mL, 47.6 mmol). The reaction time was for 2 hours. The resin was washed with DMF (3 times),

30

dichloromethane (3 times), and DMF (3 times). Fmoc-glycine (7.0 g, 23.5 mmol) was similarly reacted with the resin supported peptide in three sequential procedures to produce Fmoc-glycyl-glycyl-glycyl-S-tritylcysteinyl-Rink amide resin. The resin was washed with dichloromethane (3 times) and dried in vacuo. Substitution analysis on a small portion of resin indicated that resin substitution was 0.13 mmol/g.

K. 1-[(Carboxyglycyl-glycyl-glycyl-S-tritylcysteinamide)methyl]-4-(2-carboethoxyethyl)-7-[(4-amidinophenyl)methyl]-3,4-dihydro-1H-1,4-benzodiazepine-2,5-dione, trifluoroacetate [12]

Fmoc-glycyl-glycyl-glycyl-S-tritylcysteinyl-Rink amide resin (53.4 g, 6.94 mmol) was treated (2 times) with 20% piperidine/DMF (75 mL, 5 min. then 15 min.) and washed with DMF (4 times). Separately, 1-(carboxymethyl)-4-(2-carboethoxyethyl)-7-[(4-amidinophenyl)methyl]-3,4-dihydro-1H-1,4-benzodiazepine-2,5-dione, hydrochloride (5.9 g, 11.36 mmol) was placed in a dry round bottom flask under an atmosphere of argon and dissolved in anhydrous DMF (75 mL). This solution was stirred and cooled to 0°C and treated with 4-methylmorpholine (1.01 mL, 9.2 mmol) followed by the dropwise addition of isobutyl chloroformate (1.13 mL, 8.7 mmol). After addition was complete, the solution was stirred at 0°C for an additional 5 minutes and added to the resin-supported peptide free amine that was generated above. The resin suspension was agitated for 3 hours. The resin was washed with DMF (6 times) and dichloromethane (3 times). The resin was treated three times with trifluoroacetic acid (40 mL) for 10 minutes, each time draining the deprotection mixture into a round bottom flask. The resin was washed twice with dichloromethane (75 mL). The dichloromethane washes were combined with the trifluoroacetic acid deprotection mixtures and the volatiles removed *in vacuo* on a rotary evaporator. The residue was treated with anhydrous chloroform several times, each time removing the chloroform *in vacuo* on a rotary evaporator. This is done until the orange/yellow color of the residue disappears, indicating reattachment of the trityl group to the cysteine sulfhydryl. The crude product was pumped on under high vacuum to yield 1-[(carboxyglycyl-glycyl-glycyl-S-tritylcysteinamide)methyl]-4-(2-carboethoxyethyl)-7-[(4-amidinophenyl)methyl]-3,4-dihydro-1H-1,4-benzodiazepine-2,5-dione, trifluoroacetate (8.4 g). The product was purified by reversed-phase C18 HPLC. The column was loaded with a DMF solution of crude product (70 mg/mL) and eluted

with a linear gradient of 0.1% TFA in 90% acetonitrile/water (solvent B) and 0.1% TFA in water (solvent A). The gradient was from 20% B/A to 45% B/A over 40 minutes. Fractions were analyzed by reversed-phase C18 HPLC and fractions containing pure product were combined and lyophilized to yield 1-[(carboxyglycyl-glycyl-glycyl-S-tritylcysteinamide)methyl]-4-(2-carboethoxyethyl)-7-[(4-amidinophenyl)methyl]-3,4-dihydro-1H-1,4-benzodiazepine-2,5-dione, trifluoroacetate as a white powder (2.41 g, 2.17 mmol, 31 % yield). Electrospray mass spectral analysis indicated a molecular ion peak ($M + H^+$) of 998 (theoretical for $C_{52}H_{56}N_9O_{10}S_1$ is 998.4).

10

L. 1-[(Carboxyglycyl-glycyl-glycyl-cysteinamide)methyl]-4-(2-carboxyethyl)-7-[(4-amidinophenyl)methyl]-3,4-dihydro-1H-1,4-benzodiazepine-2,5-dione, trifluoroacetate [13]

1-[(carboxyglycyl-glycyl-glycyl-S-tritylcysteinamide)methyl]-4-(2-carboethoxyethyl)-7-[(4-amidinophenyl)methyl]-3,4-dihydro-1H-1,4-benzodiazepine-2,5-dione, trifluoroacetate (2.38 g, 2.14 mmol) was placed in a round bottom flask and dissolved in methanol (100 mL). The stirred solution was treated with an aqueous solution of 1.0 M lithium hydroxide (8.7 mL, 8.7 mmol) at room temperature for 20 hours. Trifluoroacetic acid (0.67 mL, 8.7 mmol) was added to quench the reaction and the volatiles were removed *in vacuo* on a rotary evaporator. The residue was treated with a 91:4:5 mixture of trifluoroacetic acid/triethylsilane/water (100 mL) for 45 minutes. The volatiles were removed *in vacuo* on a rotary evaporator. The residue was dissolved in 0.1% TFA in 90% acetonitrile/water (20 mL) and the stirred solution was diluted with 0.1% TFA in water (200 mL). The resulting precipitate was filtered off through a pad of Celite, which was washed with additional 0.1% TFA in water (100 mL). The combined filtrates were purified (in portions) by preparative reversed-phase C18 HPLC. The column was eluted with a linear gradient of 100% A to 15% B/A over 40 minutes (0.1% TFA in water is solvent A and 0.1% TFA in 90% acetonitrile/water is solvent B). Fractions were analyzed by reversed-phase C18 HPLC and fractions containing pure product were combined and lyophilized to yield 1-[(carboxyglycyl-glycyl-glycyl-cysteinamide)methyl]-4-(2-carboxyethyl)-7-[(4-amidinophenyl)methyl]-3,4-dihydro-1H-1,4-benzodiazepine-2,5-dione, trifluoroacetate as a white powder (1.08 g, 12.4 mmol, 58 % yield).

EXAMPLE 2**Placebo Vial Method for Radiolabeling with Technetium-99m**

5 Approximately 100 µg of the benzodiazepine derivative compound of Example 1 as 100 µL of a 1 mg/mL TFA salt solution dissolved in 0.9% saline was added to a "placebo vial", containing lyophilized 5 mg sodium glucoheptanate dihydrate, 50 µg stannous chloride dihydrate, and 100 µg sodium edetate dihydrate. The vial was then reconstituted with ^{99m}Tc-sodium pertechnetate (30 to 50 mCi) and
10 saline such that the total volume was 1.1 mL. Following reconstitution, the vials were incubated at room temperature for 30 minutes.

 The purity of the ^{99m}Tc-labeled benzodiazepinedione derivative was determined by reverse-phase analytical HPLC using the following conditions: a Waters Delta Pak C18, 5 µ, 3.9 mm x 150 mm analytical column was loaded with
15 each radiolabeled peptide, and the peptides eluted at a solvent flow rate equal to 1.2 mL/min. Gradient elution was performed using a linear gradient of 12-25% Solvent B/Solvent A (Solvent A is 0.1% (v/v) trifluoroacetic acid (TFA) in water and Solvent B is 0.1% (v/v) TFA in 90/10 (v/v) acetonitrile/water) over 20 minutes; followed by a linear gradient of 25-100% Solvent B/Solvent A over four minutes and 100% Solvent
20 B/Solvent A for three minutes (Method 1).

 Radioactive components were detected in the HPLC method using an in-line radiometric detector linked to a computerized data collection and analysis system (Waters Millennium). ^{99m}Tc-glucoheptate, ^{99m}Tc-edetate, and ^{99m}Tc-sodium
pertechnetate elute between one and four minutes under these conditions, whereas the
25 ^{99m}Tc-labeled benzodiazepinedione derivatives eluted after a much greater time. The radiochemical purity (as determined by the % area of the main ^{99m}Tc product peaks) was ≥ 90%.

 The purity of the ^{99m}Tc-labeled benzodiazepinedione derivative was also determined by TLC quality control analysis. The radiolabeled peptide samples were
30 spotted at the origin of each of two Gelman ITLC-SG strips. One strip each was developed in saturated saline (SAS) and 1:1 (v:v) methanol:0.1 M ammonium acetate (MAM) and allowed to dry. The SAS strips were cut at R_f 0.75 and the MAM strip was cut at R_f 0.40. The portions of the strips were counted for radioactivity in a dose

calibrator, and the per cent activity of the top and bottom portions of each strip calculated. The radiochemical purity of each sample was calculated as follows:

$$\text{Purity by TLC} = \% \text{ bottom (SAS)} - \% \text{ bottom (MAM)}$$

The radiochemical purity by TLC was $\geq 90\%$.

5

EXAMPLE 3

Formulated Kit Method for Radiolabeling with Technetium-99m

Formulated kits were prepared by combining components in an appropriate ratio in aqueous solution, adjusting the pH to pH 7.4, dispensing 1.0 mL into glass vials, and lyophilizing. The components were dissolved in aqueous solution such that one milliliter (one vial) contained the following: 50 μg of the benzodiazepinedione derivative of Example 1 with 25 mg sodium glucoheptonate dihydrate, 50 μg stannous chloride dihydrate, 100 μg sodium edetate dihydrate, and 5 mg L-methionine. The formulated kit was reconstituted with $^{99\text{m}}\text{Tc}$ -sodium pertechnetate (45 to 55 mCi) and saline such that the total volume was 1.0 mL. Following reconstitution, the formulated kit vials were incubated at 100°C in a boiling water bath for 10 minutes, and allowed to cool for 20 minutes at room temperature.

The purity of the $^{99\text{m}}\text{Tc}$ -labeled benzodiazepinedione derivative was determined by reverse-phase analytical HPLC using the following conditions: a Zorbax 300SB C18, 4 μ , 4.6 mm x 250 mm analytical column was loaded with each radiolabeled peptide, and the peptides eluted at a solvent flow rate equal to 1.2 mL/min. Gradient elution was performed using a linear gradient of 23-46% Solvent D/Solvent C (Solvent C is 5 mM tetrabutylammonium phosphate pH 7.5 in water and Solvent D is 5 mM tetrabutylammonium phosphate pH 7.5 in 60/40 acetonitrile/water) over 20 minutes; followed by a linear gradient of 46-100% Solvent D/Solvent C over 5 minutes and 100% Solvent D/Solvent C for 5 minutes (Method 2).

Radioactive components were detected in HPLC Method 2 by the same detection methods described for Method 1 in Example 2. The radiochemical purity obtained from the formulated kit preparations (as determined by the % area of the main $^{99\text{m}}\text{Tc}$ product peaks) was $\geq 90\%$ for >6 hours.

The purity of the $^{99\text{m}}\text{Tc}$ -labeled benzodiazepinedione derivative was also determined by TLC quality control analysis as described in Example 2.

Results of HPLC and TLC analysis of the ^{99m}Tc -labeled benzodiazepinedione derivative synthesized in Example 1 are shown in Table 1.

Table 1

5 TLC and HPLC Results for ^{99m}Tc -Labeled Benzodiazepinedione

	TLC Purity (%)	HPLC Method	HPLC Retention Time (min)	HPLC Purity (%)
Example 2	99	1	10.8, 12.0	92
Example 3 ^a	99	2	11.8, 13.7	94
	100	2	11.6, 13.5	94

^aTwo entries represent two different lots of formulated kits.

10

EXAMPLE 4

In vitro Studies

^{99m}Tc -benzodiazepinedione derivative was prepared as described in Example 2.

Preparation of Platelet-Rich Plasma (PRP). In all experiments, platelets were isolated on the day of the experiment from citrated human blood. After obtaining informed consent, 27 mL of blood was withdrawn from the antecubital vein of healthy adult volunteers into a polypropylene syringe containing 3 mL of sodium citrate (3.8% w/v, pH 7.4). Universal precautions for handling biological fluids were followed. Citrated blood was transferred to a 50 mL conical centrifuge tube and centrifuged at 900 rpm (160xg) for 10 minutes to obtain PRP.

Washed Platelets. Washed platelets were prepared by centrifuging PRP at 2,200 rpm (1,400 x g) for 12 min. The platelet-poor plasma (PPP) was decanted and the resulting pellet suspended in modified Tyrodes buffer. The PPP was decanted and discarded. Modified Tyrodes buffer (0.8 mL per mL of original PRP) was immediately layered over the platelet pellet and prostaglandin E₁ (PGE₁; 1 μL of a 40 μM solution per mL of Tyrodes buffer) added to prevent platelet activation. (McLane MA, Kowalska MA, Silver L, Shattil SJ and Niewiarowski S. (1994) *Biochem J* 301: 429-426). The pellet was resuspended with a plastic Pasteur pipette. The

centrifugation step was repeated to wash the platelets that were diluted in 150 mL of Tyrodes buffer for binding assays.

Polyethyleneimine-Treated Filters. The filters (GF/C) were presoaked in 10 mM Tris-HCl (pH 9.1) polyethyleneimine (0.5%) and P829 (0.001%) for at least one
5 hour prior to assay to decrease the nonspecific binding of ^{99m}Tc labeled benzodiazepinedione derivative to the filter.

Binding of ^{99m}Tc -benzodiazepinedione derivative to Washed Platelets.
Platelets (125 μL) were incubated in silanized glass tubes for 60 min at 37°C in a shaking water bath in a total volume of 250 μL of Tyrodes buffer containing ^{99m}Tc -
10 benzodiazepinedione derivative (50, 30, 10, 7, 5, 3, 1, 0.7, 0.5, 0.3, 0.1, and 0.07 nM final concentration). To determine the binding of ^{99m}Tc -benzodiazepinedione derivative to “activated” platelets, a 10 μL aliquot of a 0.5 mM solution of ADP (20 μM final concentration), and a 10 μL aliquot of a 1:1 mixture of 250 mM CaCl_2 and MgCl_2 was added to appropriate tubes. Nonspecific binding was determined by the
15 addition of excess unlabeled benzodiazepinedione derivative (100 μM) to fully saturate the GPIIb/IIIa receptor. The ^{99m}Tc -benzodiazepinedione derivative bound to the platelets was separated from the free ^{99m}Tc -benzodiazepinedione derivative by filtration through treated GF/C Glass Fiber Filters (Cat. No. FP24-GF/C, Brandel, Gaithersburg, MD) using a Brandel Cell harvester (Cat. No. SM24T Brandel,
20 Gaithersburg MD) connected to a vacuum source (15 to 20 mm Hg). Filters were then washed with 9 mL of 10 mM Tris-HCl buffer at pH 7.8 (4°C) and counted for radioactivity in a gamma counter.

Calculations. The specific binding of ^{99m}Tc -benzodiazepinedione derivative was calculated by subtracting the nonspecific binding in the presence of excess
25 unlabeled benzodiazepinedione derivative from the total binding measured in the absence of excess benzodiazepinedione derivative. The data were plotted as a Scatchard Plot as described in Bylung DB and Yamamura HI, *Methods for receptor binding*, Ravens Press Ltd. (New York. 1990) pp. 1-32. The data points were fitted with the linear regression function in the KaleidaGraph (Synergy Software Inc.)
30 software package. The K_d values were calculated as the negative reciprocal of the slope.

Statistics. Each response variable was compared between the two factor levels in each of the two factors using a paired student's t-test from the InStat Program (GraphPad Software, San Diego, CA). The threshold p value was set to 0.05 for rejection of the null hypothesis. For the Response Variable: K_d ; Level 1: Basal (no ADP); Level 2: Activated (ADP), factor levels were compared in platelets isolated from the same individual. Experiments were run simultaneously. The platelets from four subjects were used.

The average K_d for the binding of ^{99m}Tc -benzodiazepinedione derivative to resting and activated human platelets was 30.5 nM and 13.5 nM, respectively. Thus, more ^{99m}Tc -benzodiazepinedione derivative bound to activated platelets. The average fold-increase in binding to activated platelets over all concentrations tested was 1.8, and ranged from 1.2 to 2.3 fold. The data obtained from Scatchard plots from which the K_d values were derived are summarized in Table 2.

Table 2

Kd Values for Binding to Human Platelets (nM).

	Technetium Tc 99m P424	
	Basal	ADP
Subject 1	32	15
Subject 2	20	12
Subject 3	47	20
Subject 4	23	7
Mean	30.5 ± 6	13.5 ± 3

These data demonstrate that a ^{99m}Tc -benzodiazepinedione derivative produced in accordance with the invention binds with higher potency to activated platelets than to resting platelets.

EXAMPLE 5***In Vivo* Imaging of Deep Vein Thrombosis using
a ^{99m}Tc-Labeled Benzodiazepinedione Derivative in a Canine Model**

Three mongrel dogs (25-35lb., fasted overnight) were sedated with a
5 combination of ketamine and acepromazine intramuscularly and then anesthetized with
sodium pentobarbital intravenously. In each animal, an 18-gauge angiocath was inserted
in the distal half of the right femoral vein and an 8mm Dacron®-entwined stainless steel
embolization coil (Cook Co., Bloomington IN) was placed in the femoral vein at
approximately mid-femur. The catheter was removed, the wound sutured and the
10 placement of the coil documented by X-ray. The animals were then allowed to recover
overnight.

One day following coil placement, each animal was re-anesthetized, intravenous
saline drips placed in each foreleg and a urinary bladder catheter inserted to collect urine.
The animal was placed supine under a gamma camera which was equipped with a low-
15 energy, all purpose collimator and photopeaked for ^{99m}Tc.

The benzodiazepinedione derivative of Example 1 was labeled with ^{99m}Tc
[185-370 mBq (5-10 mCi)] and injected sequentially into one foreleg intravenous line at
its point of insertion. The second line was maintained for blood collection.

Gamma camera imaging was started simultaneously with injection. Anterior
20 images over the heart were acquired as a dynamic study (10 second image acquisitions)
over the first 10 minutes, and then as static images at 1, 2, 3 and 4 hours post-injection.
Anterior images over the legs were acquired for 500,000 counts or 20 minutes
(whichever was shorter), at approximately 10-20 minutes, and at approximately 1, 2, 3
and 4 hours post-injection. Leg images were collected with a lead shield placed over the
25 bladder.

Following the final image, each animal was deeply anesthetized with
pentobarbital. Two blood samples were collected on a cardiac puncture using a
heparinized syringe followed by a euthanizing dose of saturated potassium chloride
solution administered by intercardiac or bolus intravenous injection. The femoral vein
30 containing the thrombus, a similar section of vein of the contralateral (control) leg,
sections of the vessel proximal to the thrombus and samples of thigh muscle were then
carefully dissected out. The thrombus, coil and coil Dacron fibers were then dissected
free of the vessel. The thrombus, saline-washed vessel samples, coil and coil Dacron

fibers were separated, and each sample was placed in a pre-weighed test tube. The samples were weighed and counted in a gamma well counter in the Tc-99m channel, along with known fractions of the injected doses.

5 Fresh thrombus weight, percent injected dose (%ID)/g in the thrombus and blood obtained just prior to euthanasia and thrombus/blood and thrombus/muscle ratios were determined. From the computer-stored images, thrombus/background ratios were determined by analysis of the counts/pixel measured in regions-of-interest (ROI) drawn over the thrombus and adjacent muscle. Tissue data from these experiments are shown in Table 3.

10

Table 3Canine Model of Pulmonary Embolism and Deep Vein Thrombosis¹

	Leg Thrombus	Lung Thrombus
Thrombus/Background ²	4.2 (n=2)	1.3 (n=1)
%ID/g Thrombus	0.050 ± 0.020	0.15 ± 0.048
Thrombus/Blood ³	9.1 ± 4.6	27 ± 9
Thrombus/Muscle ³	30 ± 15	--
Thrombus/Normal Lung ³	--	29 ± 9
Thrombus Weight	430 ± 210 mg	30 ± 15 mg

¹Mean ± standard deviation

²From analysis of image regions of interest

15 ³Ratio of % injected dose/g (%ID/g)

These results demonstrate that pulmonary emboli and deep vein thrombi can be rapidly and efficiently located *in vivo* using Tc-99m labeled benzodiazepinedione derivatives of the invention.


20

It should be understood that the foregoing disclosure emphasizes certain specific embodiments of the invention and that all modifications or equivalents thereto are within the spirit and scope of the invention as set forth in the appended claims.

CLAIMS


1. A compound comprising a glycoprotein IIb/IIIa receptor binding benzodiazepine derivative covalently linked to a metal ion chelator, wherein the compound retains substantial potency for inhibition of human platelet aggregation, as measured in a standard inhibition of platelet aggregation assay.

2. The compound of claim 1, having a formula:




- where R^1 is C_1 - C_8 lower alkyl, R^2 , R^3 , R^4 , R^5 , and R^6 are each independently H, C_1 - C_8 lower alkyl, substituted alkyl, aryl, substituted aryl, or a combination thereof; L^1 is a linking moiety; Q is a positively charged nitrogen-containing moiety; and M is a metal ion chelator.

3. The compound of claim 1, having a formula:




- where R^2 is C_1 - C_8 lower alkyl, R^1 , R^3 , R^4 , R^5 , and R^6 are each independently H, C_1 - C_8 lower alkyl, substituted alkyl, aryl, substituted aryl, or a combination thereof; L^1 is a linking moiety; Q is a positively charged nitrogen-containing moiety; and M is a metal ion chelator.

4. The compound of claim 1, having a formula:




- where R^3 is C_1 - C_8 lower alkyl; $R^1, R^2, R^4, R^5,$ and R^6 are each independently H, C_1 - C_8 lower alkyl, substituted alkyl, aryl, substituted aryl, or a combination thereof; L^1 is a linking moiety; Q is a positively charged nitrogen-containing moiety; and M is a metal ion chelator.

5. The compound of claim 1, having a formula:




- 10 where R^4 is C_1 - C_8 lower alkyl; $R^1, R^2, R^3, R^5,$ and R^6 are each independently H, C_1 - C_8 lower alkyl, substituted alkyl, aryl, substituted aryl, or a combination thereof; L^1 is a linking moiety; Q is a positively charged nitrogen-containing moiety; and M is a metal ion chelator.

6. The compound of claim 1, having a formula:



where R⁵ is C₁-C₈ lower alkyl; R¹, R², R³, R⁴, and R⁶ are each independently H, C₁-C₈ lower alkyl, substituted alkyl, aryl, substituted aryl, or a combination thereof; L¹ is a linking moiety; Q is a positively charged nitrogen-containing moiety; and M is a metal ion chelator.

7. The compound of claim 1, having a formula:



10


where R⁶ is C₁-C₈ lower alkyl; R¹, R², R³, R⁴, and R⁵ are each independently H, C₁-C₈ lower alkyl, substituted alkyl, aryl, substituted aryl, or a combination thereof; L¹ is a linking moiety; Q is a positively charged nitrogen-containing moiety; and M is a metal ion chelator.

15

8. The compound of claim 1, wherein the chelator comprises a single thiol-containing group.

9. The compound of claim 8, wherein the single thiol-containing group has a formula:


20



wherein A is H, HOOC-, H₂NOC-, -NHOC-, -OOC-, R^e₂NOC-, or R^d; B is H, SH,

$-\text{NHR}^c$, $-\text{N}(\text{R}^c)-$ or R^d ; Z is H or R^d ; X is SH, $-\text{NHR}^c$, $-\text{N}(\text{R}^c)-$ or R^d ; R^a , R^b , R^c and R^d are independently H, straight chain C_1 - C_8 alkyl, branched chain C_1 - C_8 alkyl, or cyclic C_3 - C_8 alkyl; n is 0, 1 or 2; R^e is C_1 - C_4 alkyl, an amino acid, or a peptide comprising 2 to about 10 amino acids; and: (1) where B is $-\text{NHR}^c$ or $-\text{N}(\text{R}^c)-$, X is SH and n is 1 or 2; (2) where X is $-\text{NHR}^c$ or $-\text{N}(\text{R}^c)-$, B is SH and n is 1 or 2; (3) where B is H or R^d , A is $\text{HOOC}-$, $\text{H}_2\text{NOC}-$, $-\text{NHOC}-$, or $-\text{OOC}-$, X is SH and n is 0 or 1; (4) where A is H or R^d , then where B is SH, X is $-\text{NHR}^c$ or $-\text{N}(\text{R}^c)-$ and where X is SH, B is $-\text{NHR}^c$ or $-\text{N}(\text{R}^c)-$ and n is 1 or 2; (5) where X is H or R^d , A is $\text{HOOC}-$, $\text{H}_2\text{NOC}-$, $-\text{NHOC}-$, or $-\text{OOC}-$ and B is SH; (6) where Z is methyl, X is methyl, A is $\text{HOOC}-$, $\text{H}_2\text{NOC}-$, $-\text{NHOC}-$, or $-\text{OOC}-$ and B is SH and n is 0; and (7) where B is SH, X is not SH and where X is SH, B is not SH.

10. A compound having a formula:




15

wherein M is a metal ion chelator.

11. The compound of claim 10, wherein M is selected from the group consisting of:


a)



wherein $(\text{amino acid})^1$ and $(\text{amino acid})^2$ are each independently any primary α - or β -amino acid that does not comprise a thiol group, Z^1 is selected from the group consisting of cysteine, homocysteine, isocysteine, penicillamine, 2-mercaptoethylamine, 2-

mercaptopropylamine, 2-mercapto-2-methylpropylamine, and 3-mercaptopropylamine, and R¹ is lower (C¹-C⁴) alkyl, or R¹-CO is an amino acid, a peptide, or (aa)-peptide; wherein when Z¹ is cysteine, homocysteine, isocysteine or penicillamine, Z¹ comprises a carbonyl group covalently linked to a hydroxyl group, a NR³R⁴ group, wherein each of
 5 R³ and R⁴ are independently H, a bond, lower (C¹-C⁴) alkyl, an amino acid or a peptide comprising from 2 to 10 amino acids; and

b)



wherein (amino acid)¹ and (amino acid)² are each independently any primary α- or β-
 10 amino acid that does not comprise a thiol group Y is selected from the group consisting of cysteine, homocysteine, isocysteine, penicillamine, 2-mercaptoacetate, 2-mercaptopropionate, 2-mercapto-2-methylpropionate, 3-mercaptopropionate, and R² is H, a bond, lower (C¹-C⁴) alkyl, and NHR² is an amino acid, a peptide, or (aa)-peptide; wherein when Y is cysteine, homocysteine, isocysteine or penicillamine, Y comprises an
 15 amino group covalently linked to -H, an amino acid, a peptide, or (aa)-peptide.

12. The compound of claim 10, wherein M is selected from the group consisting of:

-Gly-Gly-Cys-, -Gly-Gly-Cys.amide, Gly-Gly-Cys-, Cys-Gly-Gly-,
 20 -Gly-Gly-Gly-Cys (SEQ ID NO: 1), -Gly-Gly-Gly-Cys.amide (SEQ ID NO:1), Arg-Gly-Cys-, -(ε-Lys)-Gly-Cys-, -(δ-Orn)-Gly-Cys-, -(γ-Dab)-Gly-Cys-, and -(β-Dap)-Lys-Cys-

13. The compound of claim 10, wherein M is -Gly-Gly-Gly-Cys.amide (SEQ
 25 ID NO:1).

14. A pharmaceutical composition comprising 1-[(carboxyglycyl-glycyl-glycyl-cysteinamide)methyl]-4-(2-carboxyethyl)-7-[(4-amidinophenyl)methyl]-3,4-dihydro-
 1H-1,4-benzodiazepine-2,5-dione trifluoroacetate.

30

15. The composition of claim 14, further comprising ^{99m}Tc.

16. A scintigraphic imaging agent comprising a γ -emitting radionuclide and a compound comprising a glycoprotein IIb/IIIa receptor binding benzodiazepine covalently linked to a metal ion chelating moiety, wherein the compound retains substantial potency for inhibition of human platelet aggregation, as measured in a standard inhibition of platelet aggregation assay.

17. The agent of claim 16, wherein the radionuclide is ^{99m}Tc .

18. A complex of a γ -emitting radionuclide and a compound comprising a glycoprotein IIb/IIIa receptor binding benzodiazepine covalently linked to a metal ion chelating moiety, wherein the compound retains substantial potency for inhibition of human platelet aggregation, as measured in a standard inhibition of platelet aggregation assay.

19. The complex of claim 18, wherein the radionuclide is ^{99m}Tc .

20. A ^{99m}Tc chelate of a compound comprising a glycoprotein IIb/IIIa receptor binding benzodiazepine covalently linked to a metal ion chelating moiety, wherein:

- a) the compound retains substantial potency for inhibition of human platelet aggregation, as measured in a standard inhibition of platelet aggregation assay; and
b) the chelate contains at least one sulfur ligand bound to ^{99m}Tc .

21. A method of detecting a thrombus in a mammalian body, comprising the steps of administering an effective diagnostic amount of the composition of claim 15 to the body and detecting radiation localized at the thrombus.

22. A method of detecting a thrombus in a mammalian body, comprising the steps of administering an effective diagnostic amount of the agent of claim 17 to the body and detecting radiation localized at the thrombus.

23. A method of detecting a thrombus in a mammalian body, comprising the steps of administering an effective diagnostic amount of the complex of claim 19 to the body and detecting radiation localized at the thrombus.

5 24. A method of detecting a thrombus in a mammalian body, comprising the steps of administering an effective diagnostic amount of the chelate of claim 20 to the body and detecting radiation localized at the thrombus.

25. A kit comprising a sealed vial containing:

- 10 a) a predetermined quantity of 1-[(carboxyglycyl-glycyl-glycyl-cysteinamide)methyl]-4-(2-carboxyethyl)-7-[(4-amidinophenyl)methyl]-3,4-dihydro-1H-1,4-benzodiazepine-2,5-dione trifluoroacetate; and
- b) a reducing agent.

INTERNATIONAL SEARCH REPORT

Int'l Application No PCT/US 00/10093

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K51/04 C07D243/24

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61K C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
EPO-Internal, CHEM ABS Data, BIOSIS, EMBASE, MEDLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 93 08174 A (GENENTECH INC.) 29 April 1993 (1993-04-29) cited in the application claims 2-6,10-15 & US 5 403 836 A 4 April 1995 (1995-04-04) cited in the application ---	1-25
Y	US 5 879 657 A (W. F. DEGRADO ET AL) 9 March 1999 (1999-03-09) claims 1,25-50 ---	1-25
	-/--	

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

° Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- * & * document member of the same patent family

Date of the actual completion of the international search 3 August 2000	Date of mailing of the international search report 11/08/2000
---------------------------------------------------------------------------------------	-----------------------------------------------------------------------------

Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer Siatou, E
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--------------------------------------------

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 00/10093

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>SHUANG LIU ET AL: "LABELING CYCLIC GLYCOPROTEIN IIB/IIIA RECEPTOR ANTAGONISTS WITH 99MTC BY THE PREFORMED CHELATE APPROACH: EFFECTS OF CHELATORS ON PROPERTIES OF U99MTCHELATOR-PEPTIDE CONJUGATES" BIOCONJUGATE CHEMISTRY, US, AMERICAN CHEMICAL SOCIETY, WASHINGTON, vol. 7, no. 2, 1 March 1996 (1996-03-01), pages 196-202, XP000558420 ISSN: 1043-1802 abstract page 199; figure 2</p>	1-25
A	<p>BARRETT J A ET AL: "BIOLOGICAL EVALUATION OF 99MTC-LABELED CYCLIC GLYCOPROTEIN IIB/IIIA RECEPTOR ANTAGONISTS IN THE CANINE ARTERIOVENOUS SHUNG AND DEEP VEIN THROMBOSIS MODELS: EFFECTS OF CHELATORS ON BIOLOGICAL PROPERTIES OF U99MTCHELATOR-PEPTIDE CONJUGATES" BIOCONJUGATE CHEMISTRY, US, AMERICAN CHEMICAL SOCIETY, WASHINGTON, vol. 7, no. 2, 1 March 1996 (1996-03-01), pages 203-208, XP000558421 ISSN: 1043-1802 abstract page 203; figure 1</p>	1-25
A	<p>LIU S ET AL: "LABELING A HYDRAZINO NICOTINAMIDE-MODIFIED CYCLIC IIB/IIIA RECEPTOR ANTAGONIST WITH 99MTC USING AMINOCARBOXYLATES AS COLIGANDS" BIOCONJUGATE CHEMISTRY, vol. 7, 1996, pages 63-71, XP002050942 abstract</p>	1-25
A	<p>PEARSON D A ET AL: "THROMBUS IMAGING USING TECHNETIUM-99M-LABELED HIGH-POTENCY GPIIB/IIIA RECEPTOR ANTAGONISTS. CHEMISTRY AND INITIAL BIOLOGICAL STUDIES" JOURNAL OF MEDICINAL CHEMISTRY, US, AMERICAN CHEMICAL SOCIETY, WASHINGTON, vol. 39, no. 7, 1996, pages 1372-1382, XP002061485 ISSN: 0022-2623 abstract</p>	1-25

-/--

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/10093

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>RAJOPADHYE M ET AL: "Synthesis, evaluation and Tc-99m complexation of a hydrazinonicotinyl conjugate of a gp IIb/IIIa antagonist cyclic peptide for the detection of deep vein thrombosis" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, GB, OXFORD, vol. 7, no. 8, 22 April 1997 (1997-04-22), pages 955-960, XP004136163 ISSN: 0960-894X the whole document</p> <p>---</p>	1-25
A	<p>KU T W ET AL: "DIRECT DESIGN OF A POTENT NON-PEPTIDE FIBRINOGEN RECEPTOR ANTAGONIST BASED ON THE STRUCTURE AND CONFORMATION OF A HIGHLY CONSTRAINED CYCLIC RGD PEPTIDE" JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, US, AMERICAN CHEMICAL SOCIETY, WASHINGTON, DC, vol. 115, 1993, pages 8861-8862, XP000196275 ISSN: 0002-7863 cited in the application the whole document</p> <p>---</p>	1-25
A	<p>US 5 830 856 A (R. T DEAN ET AL) 3 November 1998 (1998-11-03) cited in the application claims 1-22</p> <p>---</p>	1-25
A	<p>US 5 645 815 A (R. T. DEAN ET AL) 8 July 1997 (1997-07-08) cited in the application claims 1-25</p> <p>-----</p>	1-25

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/10093

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9308174 A	29-04-1993	US 5250679 A	05-10-1993
		AT 133412 T	15-02-1996
		AU 673501 B	14-11-1996
		AU 2797692 A	21-05-1993
		CA 2119745 A	29-04-1993
		DE 69207916 D	07-03-1996
		DE 69207916 T	17-10-1996
		DK 610334 T	03-06-1996
		EP 0610334 A	17-08-1994
		ES 2085651 T	01-06-1996
		FI 941222 A	02-06-1994
		GR 3019517 T	31-07-1996
		JP 7500341 T	12-01-1995
		NO 941378 A	20-06-1994
		US 5403836 A	04-04-1995
		US 5674865 A	07-10-1997
		US 5674863 A	07-10-1997
		US 5663166 A	02-09-1997
US 5565449 A	15-10-1996		
US 5879657 A	09-03-1999	AT 194293 T	15-07-2000
		AU 689643 B	02-04-1998
		AU 3452595 A	21-03-1996
		AU 6524894 A	24-10-1994
		BG 100036 A	29-11-1996
		BR 9406055 A	10-09-1996
		BR 9406820 A	10-09-1996
		CA 2159445 A	13-10-1994
		CN 1122577 A	15-05-1996
		EP 0692982 A	24-01-1996
		EP 0995761 A	26-04-2000
		FI 954655 A	02-11-1995
		HU 72889 A	28-06-1996
		JP 3042887 B	22-05-2000
		JP 8509710 T	15-10-1996
		LV 11106 A	20-04-1996
		LV 11106 B	20-04-1997
		NO 953886 A	30-11-1995
		NZ 263970 A	25-09-1996
		PL 311037 A	22-01-1996
		US 6010679 A	04-01-2000
		WO 9422494 A	13-10-1994
		US 5744120 A	28-04-1998
		US 5750088 A	12-05-1998
US 6015904 A	18-01-2000		
US 6022523 A	08-02-2000		
RO 114895 A	30-08-1999		
ZA 9402262 A	02-10-1995		
US 5830856 A	03-11-1998	AU 709306 B	26-08-1999
		AU 2764295 A	04-01-1996
		CA 2191949 A	14-12-1995
		EP 0772460 A	14-05-1997
		JP 10501236 T	03-02-1998
		WO 9533496 A	14-12-1995
		US 6022520 A	08-02-2000
		ZA 9504549 A	26-02-1996
AU 687080 B	19-02-1998		

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No PCT/US 00/10093

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5830856	A	AU 7241394 A	08-11-1994
		CA 2160120 A	27-10-1994
		EP 0693941 A	31-01-1996
		JP 2954355 B	27-09-1999
		JP 8508999 T	24-09-1996
		SG 49788 A	15-06-1998
		WO 9423758 A	27-10-1994
		US 5645815 A	08-07-1997
		US 6056940 A	02-05-2000
		US 5997845 A	07-12-1999
		ZA 9402439 A	08-01-1996
		AT 188387 T	15-01-2000
		AU 658617 B	27-04-1995
		AU 1411792 A	07-09-1992
		CA 2101942 A	09-08-1992
		DE 69230525 D	10-02-2000
		DE 69230525 T	21-06-2000
		EP 0570493 A	24-11-1993
		ES 2141102 T	16-03-2000
		JP 2774378 B	09-07-1998
		JP 6503352 T	14-04-1994
		US 5552525 A	03-09-1996
		US 5561220 A	01-10-1996
		WO 9213572 A	20-08-1992
		US 5997844 A	07-12-1999
		US 5654272 A	05-08-1997
		US 5849260 A	15-12-1998
		US 5849261 A	15-12-1998
		US 5714579 A	03-02-1998
		US 5788960 A	04-08-1998
US 5681541 A	28-10-1997		
US 5879658 A	09-03-1999		
US 5888474 A	30-03-1999		
US 5811394 A	22-09-1998		
US 5736122 A	07-04-1998		
US 6019958 A	01-02-2000		
US 6074627 A	13-06-2000		
US 5645815	A	08-07-1997	
		US 6056940 A	02-05-2000
		US 5997845 A	07-12-1999
		AU 687080 B	19-02-1998
		AU 7241394 A	08-11-1994
		CA 2160120 A	27-10-1994
		EP 0693941 A	31-01-1996
		JP 2954355 B	27-09-1999
		JP 8508999 T	24-09-1996
		SG 49788 A	15-06-1998
		WO 9423758 A	27-10-1994
		US 6022520 A	08-02-2000
		US 5830856 A	03-11-1998
		ZA 9402439 A	08-01-1996
		AT 188387 T	15-01-2000
		AU 658617 B	27-04-1995
		AU 1411792 A	07-09-1992
		CA 2101942 A	09-08-1992
		DE 69230525 D	10-02-2000
		DE 69230525 T	21-06-2000
EP 0570493 A	24-11-1993		

INTERNATIONAL SEARCH REPORT

information on patent family members

Inte: onal Application No

PCT/US 00/10093

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5645815 A		ES 2141102 T	16-03-2000
		JP 2774378 B	09-07-1998
		JP 6503352 T	14-04-1994
		US 5552525 A	03-09-1996
		US 5561220 A	01-10-1996
		WO 9213572 A	20-08-1992
		US 5997844 A	07-12-1999
		US 5654272 A	05-08-1997
		US 5849260 A	15-12-1998
		US 5849261 A	15-12-1998
		US 5714579 A	03-02-1998
		US 5788960 A	04-08-1998
		US 5681541 A	28-10-1997
		US 5879658 A	09-03-1999
		US 5888474 A	30-03-1999
		US 5811394 A	22-09-1998
		US 5736122 A	07-04-1998
		US 6019958 A	01-02-2000
		US 6074627 A	13-06-2000
